Results 31 to 40 of about 177,264 (261)

Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis. [PDF]

Transl Androl Urol, 2022
Goh HJ, Sung JM, Lee KH, Jo JK, Kim KN.
europepmc   +3 more sources

Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. [PDF]

BMJ Open, 2021
Pyrgidis N, Mykoniatis I, Haidich AB, Tirta M, Talimtzi P, Kalyvianakis D, Ouranidis A, Hatzichristou D.   +7 more
europepmc   +3 more sources

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management? [PDF]

The World Journal of Men's Health, 2020
Nicola Mondaini
doaj   +2 more sources

Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trials. [PDF]

Syst Rev
Zhang Y, Peng H, Xin S, Mao J, Zhang J, Li H, Luan Y, Liu X, Wang T, Liu J, Zhang H, Song W.   +11 more
europepmc   +2 more sources

Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2018
Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y.   +8 more
europepmc   +2 more sources

The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors

Andrology, 2022
Erectile dysfunction is associated with diabetes mellitus with an estimated prevalence of 52.5% in the diabetic population. The first‐line therapy for erectile dysfunction is phosphodiesterase type 5 inhibitors, but data suggest that diabetic men may be ...
A. Cayetano-Alcaraz, T. Tharakan, Runzhi Chen, N. Sofikitis, S. Minhas   +4 more
semanticscholar   +1 more source

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. [PDF]

Eur Cardiol, 2018
Watanabe H.
europepmc   +2 more sources

Why humans need type 5 phosphodiesterase inhibitors [PDF]

International Journal of Andrology, 2005
SummaryErectile dysfunction (ED) is a widespread medical condition affecting millions of males at any age and requiring medical treatment. ED may simply reflect a limit of human physiology, yet ED equates to genetic death and the high prevalence of ED is a clear evolutionary paradox.
CELLERINO, Alessandro, JANNINI E. A.
openaire   +3 more sources

Safety and Effectiveness of Repeated Botulinum Toxin A Intracavernosal Injections in Men with Erectile Dysfunction Unresponsive to Approved Pharmacological Treatments: Real-World Observational Data

Toxins, 2023
Intracavernosal injections of botulinum toxin A (BTX/A ic) may be effective for difficult-to-treat erectile dysfunction (ED). This is a retrospective case series study of the effectiveness of repeated off-label BTX/A ic (onabotulinumtoxinA 100U ...
François Giuliano, Pierre Denys, Charles Joussain   +2 more
doaj   +1 more source

Phosphodiesterase Inhibitors: Present and Future

Barcelona Respiratory Network Reviews, 2023
Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj   +1 more source